Navigation Links
Labtec’s Next Generation Pain Patch Successful in Clinical,Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld, Germany), a specialty pharmaceutics company announces positive results from a multiple dose clinical study for their proprietary Sufentanil transdermal patch.

“Today, we are pleased to announce the successful completion of the second clinical trial for our Sufentanil TDS®. Our goal for this program was to complete this study in the first half of 2007,” says Dr. Armin Breitenbach, Labtec's Director of Pharmaceutical Development. “Based on the positive results of the first Phase I trial for our Sufentanil patch that showed good safety, tolerability and extended drug release, we initiated this trial end of last year. The objectives to demonstrate effective plasma levels and safety of repetitive applications of our Sufentanil patch were fully met. We believe that this product, once approved, will provide a significant improvement over currently available pain management therapies on the market today.”

Labtec's transdermal Sufentanil product is intended to provide extended chronic pain relief for several days. The patch is not only very small but at the same time has an unusually low drug content. The proprietary formulation releases the drug with an unparalleled efficiency. Additional patient comfort is achieved by the use of a special non-woven backing. Unlike most backing films used in transdermal systems, this material is non-occlusive, allows the skin to breathe and maintains its integrity throughout the application period.

“After the huge success story of our Fentanyl patch, which is marketed by our licensee ratiopharm and several other leading generic companies in Europe, we are looking forward to see our Sufentanil TDS® move forward. In our opinion this transdermal patch is the logical next generation product for severe chronic pain. Sufentanil is one of the most potent drugs in its class,
'"/>




Page: 1 2

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
4. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
5. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
6. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Labtec Next Generation Pain Patch Successful Clinical Studies
(Date:11/6/2009)...ll/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin ...roved reverse split of its common stock will take ...2009 on a 1-for-15 split-adjusted basis. Oxygen Bi...w symbol OXBT. The stock also will have a new CUSI...ctive. ,, "This reverse split was overwhelmingl...
(Date:11/6/2009)...PRNewswire/ -- In consultation with the U.S. Food ...lthcare, Division of McNEIL-PPC, Inc., is initiati...ct lots of TYLENOL® Arthritis Pain Caplet 100...AP. McNeil is initiating the recall after identify...with these lots that led to a small number of cons...
(Date:11/6/2009)...Therapeutics, Inc. announced today that it has fil....S. Securities and Exchange Commission (SEC) relat...s of its common stock. All shares of the common st...the Company. ,, Credit Suisse Securities (USA) ...Jaffray & Co. is acting as co-lead manager and...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 1Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 2Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 3Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 4Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 5Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 6Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 7Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 8SIGVARIS USA Extends Educational Efforts in Healthy Advices Skin Care Network 55860 1SIGVARIS USA Extends Educational Efforts in Healthy Advices Skin Care Network 55860 2SIGVARIS USA Extends Educational Efforts in Healthy Advices Skin Care Network 55860 3New Medical Technology Company CareFusion Spins Off From Cardinal Health Begins Trading on NYSE 55856 1New Medical Technology Company CareFusion Spins Off From Cardinal Health Begins Trading on NYSE 55856 2
...ating to Company Oncology Programs to be Presented...ewswire-FirstCall/ -- Cytokinetics, Incorporated a...inical data will be,presented at the 2007 Annual M...arch (AACR) to be held from April 14- 18, 2007 in,...iple oncology,programs at Cytokinetics and will pr...
...(BUSINESS WIRE)--Apr 10, 2007 - Inotek,Pharmaceuti...n the,journal Stroke of preclinical animal data sh...) polymerase (PARP) inhibitor,has a large protecti...ollowing a stroke. PARP is a nuclear enzyme that d...n and recruitment of DNA,repair enzymes and has po...
Other Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3
(Date:11/8/2009)...are Reform Bill ,, Critical legislation would...ricans ,, CHICAGO, Nov. 7 /PRNewswire-USNewswi...atives passed by a vote of 220-215, critical healt...dicare for seniors and end discrimination by insur...ut of affordable health coverage. ,, The Affo...
(Date:11/7/2009)...re/ -- Karen Ignagni, President and CEO of America...lowing statement today on House passage of H.R. 39...sive health care reform, and we have contributed t... of how health insurance is provided. Earlier this...n of pre-existing condition exclusions, no longer ...
(Date:11/7/2009)...ok (GA), Louis J. Goodman (TX), Palmer P. Jones (N...ov. 7 The American Medi... society executive leaders with achievement awards...als of the medical profession. The awards were pre...ing in Houston. ,, (Logo: http://www.newscom...
(Date:11/7/2009)...ponsibility to vigorously oppose abortion in healt...INGTON, Nov. 7 Ameri... following statement on the news that Cardinal Jus...ordable Health Care for America Act (H.R. 3962), p... abortion is voted upon. ,, "Our Catholic bish...
(Date:11/7/2009)...ty of America (PRSA) will bestow the distinguished...e president of Brand Strategy, Communications and ... PRSA,s 2009 International Conference in San Diego...llows is one of the profession,s highest individua...PRSA, and 2009 chair of the College of Fellows. "I...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3
...LIN, N.J., April 21 Pharmos Corporation (Pink S... a private placement of common stock and warrants....ares of common stock and warrants exercisable for ...year term, is $0.12 per share. , , The three purc...
...Los Angeles Exposition Park , , LOS ANGE...Dimes premier fundraising event that benefits all ... to survive and thrive. 11,000 walkers are expecte...les, CA this Saturday, April 25. , , (Logo: http...
... YORK, April 21 Carl Icahn announced today that h... Jr., Chairman of the Board and James Wilson, Lead...nc. (Nasdaq: AMLN ) concerning recent discussion...irman of the Board, James Wilson, Lead Independ...
... YORK, April 21 Immtech Pharmaceuticals, Inc. (NY...is reorganizing its R&D operations. This restr...nities based on the Company,s ongoing discovery pr...l Development & Chief Medical Officer is being...
...ng contradicts belief that process favors people i...hDay News) -- People with kidney failure who live ...t a kidney transplant than people in urban areas, ...d 2007. After about two years on the list, 122,785...
... finds fewer complications with electrophysiologis...-- Chances are you,ve never heard of electrophysio...now about if you are one of the 100,000 or so Amer...rly. And the incidence of in-hospital complication...
Other Medicine News:Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Icahn Responds to Cook and Wilson 2Health News:Icahn Responds to Cook and Wilson 3Health News:Icahn Responds to Cook and Wilson 4Health News:Immtech to Reorganize Research and Development Operations 2Health News:Immtech to Reorganize Research and Development Operations 3Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Doctor's Training Affects Defibrillator Implant Results 2Health News:Doctor's Training Affects Defibrillator Implant Results 3
Hemmingway
Kerpel
Endocrette Endocervical Curette
London Endocervical Curette
Medicine Products: